77 results on '"Hudes G"'
Search Results
2. M411 ACTIVE TUBERCULOSIS (TB) MASQUERADING AS AN ASTHMA EXACERBATION DURING A SARS-COV-2 (COVID 19) PANDEMIC
3. M405 COVID-19 ASSOCIATED EOSINOPHILIC LICHEN PLANUS
4. P226 EFFECT OF OMALIZUMAB IN ASTHMA PATIENTS BY NUMBER OF ASTHMA-RELATED AND ALLERGIC COMORBIDITIES IN PROSPERO
5. M304 SOY MILK ANAPHYLAXIS IN PATIENTS WITH NEGATIVE SOY SPECIFIC IGE AND SKIN TEST: DIAGNOSTIC CHALLENGE
6. DELAYED URTICARIA AND ANGIOEDEMA FOLLOWING YELLOW FEVER VACCINE IMMUNIZATION
7. P345 Systemic contact dermatitis resulting from patch testing to vanadium
8. P049 Acute interstitial pneumonitis following talc-pleurodesis
9. E2809. Androgen receptor (AR) modulation by bicalutamide (Bic) and MK-2206 (MK) in prostate cancer (PC) patients (pts) with rising PSA at high risk of progression after local treatment (tx)
10. The Urticaria Severity Score May Serve As An Early Clinical Indicator In Monitoring Patients With Chronic Urticaria
11. Effect of EGFR inhibition with cetuximab (CET) on the efficacy of paclitaxel (TAX) in previously treated metastatic (MET) urothelial cancer.
12. The prognostic significance of prenephrectomy absolute lymphocyte count in clear cell renal cell carcinoma.
13. Effect of EGFR inhibition with cetuximab on the efficacy of paclitaxel in previously treated metastatic urothelial cancer.
14. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial.
15. ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).
16. Novel early stopping rule uses early progression rather than lack of response as rapid assessment for futility.
17. Association Between Asthma-related Emergency Department Visits And Mold Spore Or Pollen Concentrations In The Bronx
18. 7108 Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12–0605/NCT00515697)
19. 7113 Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus
20. 7134 Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial
21. Dose intensity of cisplatin and gemcitabine (CG) for muscle invasive urothelial bladder cancer (MIUBC) in the neoadjuvant versus adjuvant settings: The Fox Chase Cancer Center (FCCC) experience
22. A phase I study of temsirolimus (TEM) and bryostatin (BRYO) in patients with metastatic renal cell carcinoma (RCC)
23. A phase I study of CNTO328, an anti-interleukin (IL)-6 monoclonal antibody combined with docetaxel in subjects with metastatic castration-resistant prostate cancer (CRPC)
24. Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
25. Sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results from a phase I/II study
26. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma
27. Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study
28. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features
29. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone
30. Functional antibody deficiency in a patient with type I Gaucher disease
31. Allergen Immunotherapy in Three Patients with Human Immunodeficiency Virus
32. PCN64 CLINICALLY IMPORTANT DIFFERENCE IN QUALITY-ADJUSTED SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH TEMSIROLIMUS (TEMSR) OR INTERFERON-A (IFN)
33. PCN69 PATIENT-REPORTED IMPAIRMENT OF EUROQOL HEALTH STATES AND PREFERENCE-WEIGHTED UTILITY IN ADVANCED RENAL CELL CARCINOMA IN A RECENT CLINICAL TRIAL
34. 4011 POSTER Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-a or the combination of temsirolimus + interferon-a
35. 4507 ORAL Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib
36. 4520 POSTER Sunitinib plus interferon-alfa in the first-line treatment for metastatic renal cell carcinoma (mRCC): results of a dose-finding study
37. Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
38. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-α (IFN) or the combination of IFN+TEMSR
39. Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC)
40. Androgen deprivation therapy (ADT) for node postive prostate cancer
41. Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs)
42. Sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): Results of a dose-finding study
43. Preliminary results of a phase I study: A chimeric monoclonal anti IL-6 antibody CNTO 328 in combination with docetaxel in patients with hormone refractory prostate cancer
44. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach
45. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib
46. Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results of two phase II trials and prognostic factor analysis for survival
47. A Novel Case of Gaucher's Disease Associated with Hypogammaglobulinemia
48. 343 POSTER Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 24 hours infusion in a 14-day cycle in patients with advanced/metastatic solid tumor
49. A meta-analysis of individual patient data from randomized trials assessing chemotherapy with and without estramustine in patients with castration-refractory prostate cancer
50. Phase I study of intravenous CCI-779 in combination with bryostatin-1 in solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.